ERG28: A Protein Targeted for Drug and Biomarker Development (G11161)

Target Name: ERG28

NCBI ID: G11161

ERG28

ERG28: A Protein Targeted for Drug and Biomarker Development

ERG28, also known as ERG28-HUMAN, is a protein that is expressed in various tissues of the human body. It is a member of the EGFR family of transmembrane proteins, which are known for their involvement in cell signaling pathways. One of the most interesting aspects of ERG28 is its potential as a drug target or biomarker.

ERG28 is involved in several different signaling pathways, including the EGFR signaling pathway, the TGF-β signaling pathway, and the Wnt signaling pathway. This makes it an attractive target for drugs that are designed to modulate these signaling pathways.

One of the main advantages of ERG28 as a drug target is its expression in a wide range of tissues, including breast tissue, lung tissue, and brain tissue. This makes it an potential target for drugs that can be effective in treating a variety of different diseases. Additionally, ERG28 is a good candidate for a biomarker because it is highly expressed in many different types of cancer, and its levels can be used as a diagnostic marker for these diseases.

Another advantage of ERG28 as a drug target is its role in cell signaling. ERG28 is involved in several different signaling pathways, including the EGFR signaling pathway, the TGF-β signaling pathway, and the Wnt signaling pathway. This makes it an attractive target for drugs that can modulate these signaling pathways and have a variety of different effects on cell behavior.

One of the most promising aspects of ERG28 as a drug target is its potential to treat a variety of different diseases. For example, ERG28 has been shown to be involved in the development and progression of several different types of cancer, including breast cancer, lung cancer, and brain cancer. This makes it an potential target for drugs that can be effective in treating these diseases.

In addition to its potential as a drug target, ERG28 is also a potential biomarker for several different types of cancer. Its levels can be used as a diagnostic marker for breast, lung, and brain cancer, among other types of cancer. This makes it an important tool for the diagnosis and treatment of these diseases.

Overall, ERG28 is an interesting protein that is worth investigating as a potential drug target or biomarker. Its involvement in several different signaling pathways and its potential to treat a variety of different diseases make it an important target for researchers to explore. Further research is needed to fully understand the role of ERG28 in cell signaling and its potential as a drug and biomarker.

Protein Name: Ergosterol Biosynthesis 28 Homolog

The "ERG28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERG28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets